Contact Us
Drug Search Results
More Filters [+]

Taldefgrobep alfa

Alternative Names: Taldefgrobep alfa, tadefgrobep alfa, rg-6206, rg 6206, rg6206, bms-986089, bms986089, bms 986089, ro-7239361, ro 7239361, ro7239361, BHV-2000, BHV2000, BHV 2000
Latest Update: 2024-12-13
Latest Update Note: Clinical Trial Update

Product Description

For Duchenne Muscular Dystrophy; (Sourced from: https://www.chugai-pharm.co.jp/english/profile/media/conference/files/181024ePresentation.pdf)

Mechanisms of Action: GDF8 Inhibitor

Novel Mechanism: Yes

Modality: Peptide/Protein

Route of Administration: Subcutaneous

FDA Designation:
Fast Track - Muscular Atrophy, Spinal|Muscular Atrophy
Orphan Drug - Muscular Atrophy, Spinal|Muscular Atrophy *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: Bristol-Myers Squibb

Clinical Description

Map of Global Clinical Trials for Taldefgrobep alfa

Countries in Clinic: Belgium, Czech Republic, Germany, Italy, Netherlands, Poland, Spain, United Kingdom, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 3: Muscular Atrophy, Spinal|Spinal Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
RESILIENT

P3

Active, not recruiting

Muscular Atrophy, Spinal

2025-11-02

BHV2000-301

P3

Unknown Status

Muscular Atrophy, Spinal

2025-10-08

RESILIENT

P3

Active, not recruiting

Spinal Diseases|Muscular Atrophy, Spinal

2025-01-01

95%

Recent News Events

Date

Type

Title

05/29/2024

News Article

 Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day

02/01/2024

PubMed

 The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy.

01/08/2024

News Article

 Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncology

01/01/2024

PubMed

 Stride Velocity 95th Centile Detects Decline in Ambulatory Function Over Shorter Intervals than the 6-Minute Walk Test or North Star Ambulatory Assessment in Duchenne Muscular Dystrophy.

11/14/2023

News Article

 Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments

09/14/2023

News Article

 Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy

08/01/2020

PubMed

 Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions